Weight-loss guide
Two medicines. One dose we will print.
Position 1 on 2026-10-16 was an obesity-medicine comparison. We did not copy it. Semaglutide numbers below are the Wegovy label. Tirzepatide milligrams are not on this page.
The comparison the files support
| Semaglutide, Wegovy label | Tirzepatide | |
|---|---|---|
| What it is | GLP-1 receptor agonist, injection and tablets on that label. | A different medicine. We do not describe its receptors from memory. |
| Brand injection schedule | Start 0.25 mg once weekly for 4 weeks, then escalate. Usual maintenance 2.4 mg once weekly. | Not printed. |
| Boxed warning on the file we opened | Thyroid C-cell tumors in rodents. Do not start with a personal or family history of medullary thyroid carcinoma, or with MEN 2. | Not copied across. Open that label before printing its warning. |
| Compounded | Not the Wegovy pen. | Not an FDA-approved finished product, if a clinician prescribes it. |
Guides: compounded semaglutide and tirzepatide.
References
Opened 2026-10-16.
- DailyMed: Wegovy.
- Who ranks: Obesity Medicine Association. Not copied. Tirzepatide dose left blank.
About Mendoxa
- Mendoxa serves 49 U.S. states. Not available in California.
- A licensed clinician can say no. A prescription is not automatic.
- When a prescription is issued, Rush Pharmacy fulfills it.
- A compounded medicine is not an FDA-approved finished product.
- The price is shown in the intake, not on this page.